Humacyte, Inc. - 8-K Filing
Humacyte reports Q3 2026 Symvess revenue of $1.0 million, a 151% sequential increase, and plans November 2026 sBLA filing for ATEV in dialysis access. (Items: 2.02 Results of Operations and Financial Condition On November 10, 2026, Humacyte, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $HUMA
Read the full article at SEC EDGAR
Part of the story SHENANDOAH TELECOMMUNICATIONS CO/VA/ - 8-K Filing (57 articles)